Nutritional Interventions in Patients With Alcohol-associated Hepatitis

Western University, Canada

Status

Not yet enrolling

Conditions

Alcoholic Hepatitis

Treatments

Dietary Supplement: Nutritional supplement

Study type

Interventional

Funder types

Other

Identifiers

NCT06131177

13698

Details and patient eligibility

About

Alcohol-associated hepatitis (AH) is a life-threatening condition with high 90-days mortality (up to 40%) and limited treatment options. Previous studies have shown that decreased nutritional intake (less than 21 kcal/kg/day) is associated to a higher mortality compared to patients with a higher caloric intake. Additionally, it has been suggested that subjects with severe AH, should receive a high-protein diet, however, no specific trials have been carried out to address these questions. Thus, the investigators aim to compare nutritional interventions through a randomized controlled trial to assess if a strategy of peripheral parental nutrition (PPN) plus oral nutritional supplementation (ONS) improves outcomes in patients with severe AH. The investigators will compare standard oral intake, enhanced oral intake with IV fluid supplementation, and PPN plus ONS in patients admitted to hospital with severe AH. These results potentially will help guide practitioners on caloric benchmarks targets for patients with severe AH. This study will also assess specific risks and benefits of different nutritional interventions.

Enrollment

2,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult (>18 years) patients admitted with acute severe AH based clinical diagnosis according to NIAAA criteria
Excessive alcohol consumption for more than 5 years in a row or interrupted
No more than 60 days of abstinence before the onset of jaundice
Bilirubin levels >3 mg/dL (>50 umol/L), AST>50 IU/mL, AST/ALT ratio > 1.5
Abstinence of other causes of liver disease
MELD score ≥ 20

Exclusion criteria

Age < 18 years
Pregnancy or lactation.
Allergy or intolerance to the enhanced oral intake formulation or PPN formulation.
Expected length of stay less than 48 hours.
Contraindications to IV fluid or PPN administration (fluid overload, suspected bacteremia).
Presence of drug-induced liver injury (DILI), ischemic hepatitis, biliary duct obstruction, viral hepatitis, autoimmune hepatitis, or Wilson's disease.
Extrahepatic neoplasia with a life expectancy of less than 6 months.
History of severe extrahepatic disease (e.g., chronic kidney failure requiring hemodialysis, severe heart disease (NYHA class ≥3), severe chronic lung disease (class ORO ≥3) that confers a survival of less than 6 months.